Isoliquiritigenin(GU17)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	961-29-5
规格:	≥98%

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议
1g	电议
2g	电议

产品介绍

理化性质和储存条件

Molecular Weight (MW)	256.25
Formula	C15H12O4
CAS No.	961-29-5
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: > 10 mM
	Water: N/A
	Ethanol: N/A
Other info	Chemical Name: (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one InChi Key: DXDRHHKMWQZJHT-FPYGCLRLSA-N InChi Code: InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+ SMILES Code: O=C(C1=CC=C(O)C=C1O)/C=C/C2=CC=C(O)C=C2
Synonyms	GU17; GU-17; GU 17

实验参考方法

In Vitro	Isoliquiritigenin may prevent diabetic complications through inhibiting rat lens aldose reductase with an IC50 of 320 nM and sorbitol accumulation in human red blood cells with an IC50 of 2.0 μM[1]. Isoliquiritigenin (100 μM) markedly inhibits the hypoxia-induced prolonged TPS and TR90 of cardiomyocytes. Isoliquiritigenin significantly triggers AMPK Thr172 phosphorylation as compared with vehicle group. Isoliquiritigenin treatment also induces extracellular signal-regulated kinase (ERK) signaling pathway in the cardiomyocytes. Isoliquiritigenin treatment significantly decreases the intracellular ROS levels of isolated cardiomyocytes during hypoxia/reoxygenation[3]. Isoliquiritigenin not only downregulates IL-6 expression but also significantly decreases levels of phosphorylated ERK and STAT3 and can inhibit phosphorylation levels of ERK and STAT3 induced by recombinant human IL-6, which are critical signaling proteins in IL-6 signaling regulation networks[4].
In Vivo	Isoliquiritigenin shows concentration-dependent inhibition of the tonic contraction of mouse jejunum induced by various types of stimulants such as CCh (1 mM), KCl (60 mM) and BaCl2 (0.3 mM) with IC50 values of 4.96±1.97 mM, 4.03±1.34 mM and 3.70±0.58 mM, respectively[2]. Isoliquiritigenin exhibits significant anti-tumor activity in MM xenograft models and synergistically enhances the anti-myeloma activity of adriamycin[4].

In Vitro

Isoliquiritigenin may prevent diabetic complications through inhibiting rat lens aldose reductase with an IC50 of 320 nM and sorbitol accumulation in human red blood cells with an IC50 of 2.0 μM[1]. Isoliquiritigenin (100 μM) markedly inhibits the hypoxia-induced prolonged TPS and TR90 of cardiomyocytes. Isoliquiritigenin significantly triggers AMPK Thr172 phosphorylation as compared with vehicle group. Isoliquiritigenin treatment also induces extracellular signal-regulated kinase (ERK) signaling pathway in the cardiomyocytes. Isoliquiritigenin treatment significantly decreases the intracellular ROS levels of isolated cardiomyocytes during hypoxia/reoxygenation[3]. Isoliquiritigenin not only downregulates IL-6 expression but also significantly decreases levels of phosphorylated ERK and STAT3 and can inhibit phosphorylation levels of ERK and STAT3 induced by recombinant human IL-6, which are critical signaling proteins in IL-6 signaling regulation networks[4].

In Vivo

Isoliquiritigenin shows concentration-dependent inhibition of the tonic contraction of mouse jejunum induced by various types of stimulants such as CCh (1 mM), KCl (60 mM) and BaCl2 (0.3 mM) with IC50 values of 4.96±1.97 mM, 4.03±1.34 mM and 3.70±0.58 mM, respectively[2]. Isoliquiritigenin exhibits significant anti-tumor activity in MM xenograft models and synergistically enhances the anti-myeloma activity of adriamycin[4].